EUVIMEDEUVIMED entdecken
Crossref

Evaluation of small interfering RNA–dependent knockdowns of drug-metabolizing enzymes in multiwell array culture of primary human hepatocyte spheroids for estimation of fraction metabolized

Lena Brücker, Dominik Jacob, Lena C Preiss, Yi Zhong, Felix Geist, Philip Hewitt, Volker M Lauschke, Carl Petersson

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Lena Brücker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chemical and Preclinical Safety, The Healthcare Business of Merck KGaA, Darmstadt, Germany; Department of Drug Metabolism and Pharmacokinetics (DMPK)…. Hauptthemen laut MEDLINE: Hepatocytes, Spheroids, Cellular, RNA, Small Interfering, Cytochrome P-450 Enzyme System. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The determination of the relative contribution of different drug-metabolizing enzymes to the metabolism of slowly metabolized compounds is a challenging task. The quantification of low compound turnover in standard in vitro systems, such as liver microsomes or hepatocyte suspension cultures, can be difficult. Thus, the use of long-term liver models, such as HepatoPac (BioIVT) or liver spheroids, has been suggested. Inhibitors of cytochrome P450 (P450) enzymes, the most important group of drug-metabolizing enzymes, represent the current standard to evaluate the route of drug metabolism. However, a long-term inhibition in systems such as spheroid models may be technically challenging due to limited stability of some of the commonly used inhibitors. Small interfering RNA (siRNA)-dependent knockdown of P450 enzymes in spheroid cultures of primary human hepatocytes represents a novel alternative to the established methods. In the current study, we report the successful attenuation of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 isoforms via siRNA on gene expression, as well as on the functional level, for at least 7 days. The analysis revealed that the knockdowns had only minor effects on the overall transcriptome. They also showed acceptable selectivity towards drug-metabolizing enzymes, except for the knockdown of CYP2C19. Applicability of the system for the determination of the fraction metabolized of low clearance substances was examined using 6 compounds metabolized by different P450s. By introducing siRNA-dependent knockdowns in phenotypically relevant primary human hepatocyte spheroid cultures, we hope to provide a novel alternative to standard systems to elucidate clearance pathways in vitro. SIGNIFICANCE STATEMENT: Small interfering RNA-mediated gene knockdowns of different cytochrome P450 enzymes were shown to be effective in long-term primary human hepatocyte spheroid cultures, representing a novel alternative for reaction phenotyping. This method has the potential to improve the assessment of pharmacokinetic variability and victim drug-drug interaction risks due to enzyme polymorphism or inhibition/induction with more confidence, particularly for low clearance drug candidates. Furthermore, minor effects of the small interfering RNA-mediated gene knockdowns for different cytochrome P450 enzymes on cell viability and the transcriptome were observed which implies that this system may be useful in deconvoluting toxicity caused by metabolites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesSpheroids, CellularRNA, Small InterferingCytochrome P-450 Enzyme SystemHumansCells, CulturedGene Knockdown TechniquesCell Culture Techniques

Stichwörter der Autor:innen

3D cell cultureCytochrome P450Low clearanceMetabolismPharmacokineticsPrimary human hepatocytesReaction phenotypingSpheroidssiRNA

Substanzen

RNA, Small InterferingCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Chemical and Preclinical Safety, The Healthcare Business of Merck KGaA, Darmstadt, Germany; Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany; Department of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet an…
  • Department of Physiology and Pharmacology and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden; Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zh…
  • Research Unit (RU) Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Chemical and Preclinical Safety, The Healthcare Business of Merck KGaA, Darmstadt, Germany.

Zitieren

APA

Brücker, L., Jacob, D., Preiss, L. C., Zhong, Y., Geist, F., Hewitt, P., Lauschke, V. M., & Petersson, C. (2025). Evaluation of small interfering RNA–dependent knockdowns of drug-metabolizing enzymes in multiwell array culture of primary human hepatocyte spheroids for estimation of fraction metabolized. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100062

Vancouver

Brücker L, Jacob D, Preiss LC, Zhong Y, Geist F, Hewitt P, et al. Evaluation of small interfering RNA–dependent knockdowns of drug-metabolizing enzymes in multiwell array culture of primary human hepatocyte spheroids for estimation of fraction metabolized. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100062

BibTeX
@article{Brcker2025,
  author = {Brücker, Lena and Jacob, Dominik and Preiss, Lena C and Zhong, Yi and Geist, Felix and Hewitt, Philip and Lauschke, Volker M and Petersson, Carl},
  title = {Evaluation of small interfering RNA–dependent knockdowns of drug-metabolizing enzymes in multiwell array culture of primary human hepatocyte spheroids for estimation of fraction metabolized},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100062}
}
Kostenlos starten →